Form 4: Director Sells TARS Shares Under 10b5-1 Plan

Director Katherine Goodrich reported a sale of 2,954 shares of Tarsus Pharmaceuticals, Inc. common stock, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Director Katherine Goodrich sold 2,954 shares of Tarsus Pharmaceuticals, Inc. common stock.
• The transaction occurred on June 15, 2026.
• The sale was executed at a price of $62.08 per share.
• This sale was made pursuant to an automatic Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2026.
• Following the transaction, Ms. Goodrich beneficially owns 2,233 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the director's sale of shares, despite the sale being executed under a pre-established 10b5-1 plan.

Negatives

• Director sale of a significant number of shares, although executed under a pre-planned 10b5-1 trading plan, could be perceived negatively by the market.

Risks

• The sale of shares by a director, even under a 10b5-1 plan, may signal a lack of confidence in future stock performance, potentially impacting investor sentiment.

Future Outlook

No forward-looking statements or guidance are present in this filing.

Industry Context

StockSavvy.ai notes that insider sales, even those conducted under Rule 10b5-1 plans, are closely watched by investors as they can sometimes precede significant price movements. The execution of such a plan indicates a pre-determined strategy for stock disposition, mitigating concerns about opportunistic selling.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the director's sale as a potential signal, though the 10b5-1 plan mitigates concerns about insider trading. The sale reduces the director's direct ownership stake.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Sale, Rule 10b5-1, Tarsus Pharmaceuticals, Katherine Goodrich, Director, Beneficial Ownership